We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
GlaxoSmithKline previously announced it would delay a phase 2b trial of its adjuvanted vaccine candidate developed with Sanofi following lackluster results. Read More
Jazz Pharmaceuticals is set to acquire GW Pharmaceuticals, a UK drugmaker known for its CBD products Epidiolex (cannabidiol) and Sativex (nabiximols), for a whopping $7.2 billion. Read More
Bristol Myers Squibb (BMS) has struck a deal with Rockefeller University for the global rights to a monoclonal antibody being developed by the university to treat COVID-19. Read More
The COVID-19 vaccine Covaxin, which was approved for emergency use in India ahead of late-stage trial results, may be coming to the U.S., as its manufacturer, Bharat Biotech, has secured a U.S. partner and plans to seek Emergency Use Authorization (EUA) from the FDA for distribution in the U.S. Read More
St. Petersburg, Russia-based Pharmsynthez has reportedly begun manufacturing a generic version of Gilead Sciences’ COVID-19 antiviral treatment Veklury (remdesivir) without the U.S. company’s permission. Read More
As the U.S. impatiently awaits delivery of many more millions of doses of the two currently authorized COVID-19 vaccines, Pfizer/BioNTech and Moderna said they are confident that they can fully deliver what’s been ordered to date in the next few months — and that they have shipped around 59.4 million doses so far. Read More